Back to top
more

Novartis (NVS)

(Real Time Quote from BATS)

$105.68 USD

105.68
589,078

-0.77 (-0.72%)

Updated Nov 11, 2024 01:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (57 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Kinjel Shah headshot

5 Large Drug Stocks to Watch as Sector Picks Up in 2023

by Kinjel Shah

Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, J&J (JNJ), Novo Nordisk (NVO), AstraZeneca (AZN), Novartis (NVS), and Sanofi (SNY) are worth retaining in your portfolio.

Lilly's (LLY) Verzenio Gets FDA Nod for Expanded Breast Cancer

by Zacks Equity Research

Eli Lilly (LLY) announces FDA approval of label expansion of Verzenio (abemaciclib), in combination with endocrine therapy, for treating HR+, HER2-, node-positive and high-risk early breast cancer.

Incyte (INCY) Discontinues Jakafi Combo Myelofibrosis Study

by Zacks Equity Research

Incyte (INCY) decides to scrap the LIMBER-304 study evaluating the efficacy and safety of parsaclisib plus Jakafi for myelofibrosis (MF) following an independent data monitoring committee recommendation.

Zacks.com featured highlights Sanofi, SK Telecom, PBF Energy, Arrow Electronics and Novartis

by Zacks Equity Research

Sanofi, SK Telecom, PBF Energy, Arrow Electronics and Novartis have been highlighted in this Screen of The Week article.

AstraZeneca (AZN) Enhertu Betters Outcomes in Multi-Tumor Study

by Zacks Equity Research

AstraZeneca (AZN) and Daiichi Sankyo' Enhertu met the pre-specified criteria for objective response rate and duration of response in the DESTINY-PanTumor02 phase II study.

Rajani Lohia headshot

These 5 Price-to-Sales Stocks Can Be Rewarding Investments

by Rajani Lohia

The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like SNY, SKM, PBF, ARW and NVS hold promise.

NVS vs. LLY: Which Stock Is the Better Value Option?

by Zacks Equity Research

NVS vs. LLY: Which Stock Is the Better Value Option?

After Plunging -7.17% in 4 Weeks, Here's Why the Trend Might Reverse for Novartis (NVS)

by Zacks Equity Research

The heavy selling pressure might have exhausted for Novartis (NVS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Bayer's (BAYRY) Q4 Earnings and Revenues Top, Outlook Weak

by Zacks Equity Research

Bayer (BAYRY) beats on earnings and sales in the fourth quarter. However, its 2023 outlook is dismal.

Alnylam (ALNY) Q4 Earnings Top, Product Sales Boost Revenues

by Zacks Equity Research

Alnylam Pharmaceuticals (ALNY) reports better-than-expected fourth-quarter 2022 results. Total revenues of the company continue to be driven by the sales of Onpattro, Givlaari, Oxlumo and the newly approved Amvuttra.

Merck (MRK) Gets Priority Tag for Antiviral Drug Prevymis sNDA

by Zacks Equity Research

The FDA grants priority review designation to Merck's (MRK) sNDA seeking expanded use of Prevymis. The PDUFA date is Jun 5, 2023.

Incyte (INCY) Reports Positive Long-Term Data From HS Study

by Zacks Equity Research

Incyte's (INCY) povorcitinib shows sustained and durable efficacy across all treatment arms in the open-label extension period of the phase II HS study.

Gilead (GILD) Kite Reports Positive Data on CAR T-Cell Therapy

by Zacks Equity Research

Gilead (GILD) reports positive long-term results from the phase I/II study on Tecartus (brexucabtagene autoleucel) for acute lymphoblastic leukemia.

Novartis (NVS) Q4 Earnings Top, Revenues Miss Estimates

by Zacks Equity Research

Novartis (NVS) reports mixed fourth-quarter results, with key brands maintaining momentum but Cosentyx sales declining and generic competition remaining a drag.

Incyte (INCY) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Incyte's (INCY) fourth-quarter 2022 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.

Can Sanofi (SNY) Keep the Beat Streak Alive in Q4 Earnings?

by Zacks Equity Research

Sanofi's (SNY) top line is likely to have been driven by higher sales of Dupixent and vaccines.

Bristol-Myers (BMY) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

Investors are likely to focus on the demand for Eliquis and Opdivo, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) reports Q4 results.

Weibo and Viasat have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Weibo and Viasat are part of the Zacks Bull and Bear of the Day article.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ Q4 Results Mixed, MRK Keytruda Prostate Cancer Study Ends

by Kinjel Shah

J&J (JNJ) reports mixed fourth-quarter results. Merck (MRK) discontinues an advanced prostate cancer study on blockbuster drug Keytruda for futility.

Is a Beat on the Cards for Novo Nordisk (NVO) in Q4 Earnings?

by Zacks Equity Research

Novo Nordisk's (NVO) top line is likely to have been driven by sales of its Diabetes and Obesity Care products in the fourth quarter of 2022.

Novartis' (NVS) Unit to Acquire Astellas' Rights of Mycamine

by Zacks Equity Research

Novartis' (NVS) generic unit Sandoz is set to acquire rights to the antifungal product Mycamine from Astellas.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

The Zacks Analyst Blog Highlights Nike, Novartis, Wells Fargo, Broadcom and Anheuser-Busch

by Zacks Equity Research

Nike, Novartis, Wells Fargo, Broadcom and Anheuser-Busch are part of the Zacks top Analyst Blog.

Sheraz Mian headshot

Top Stock Reports for NIKE, Novartis & Wells Fargo

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including NIKE, Inc. (NKE), Novartis AG (NVS) and Wells Fargo & Company (WFC).

Incyte (INCY) Up 7% in a Year: Will the Momentum Continue?

by Zacks Equity Research

Incyte (INCY) outperforms the biotech industry in the past year and the momentum is anticipated to continue in 2023 as well.